Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and …
V Escudero-Vilaplana, R Collado-Borrell… - Journal of medical …, 2023 - Taylor & Francis
Aims To assess the cost-effectiveness of adjuvant atezolizumab in the treatment of early-
stage NSCLC patients (stage II–IIIA) with expression PD-L1≥ 50% without mutations in …
stage NSCLC patients (stage II–IIIA) with expression PD-L1≥ 50% without mutations in …
[引用][C] Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and …
V Escudero-Vilaplana… - Journal of medical …, 2023 - produccioncientifica.ucm.es
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and …
V Escudero-Vilaplana, R Collado-Borrell… - Journal of Medical …, 2023 - europepmc.org
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of
patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1 …
patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1 …
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and …
V Escudero-Vilaplana… - Journal of medical …, 2023 - pubmed.ncbi.nlm.nih.gov
Aims To assess the cost-effectiveness of adjuvant atezolizumab in the treatment of early-
stage NSCLC patients (stage II-IIIA) with expression PD-L1≥ 50% without mutations in …
stage NSCLC patients (stage II-IIIA) with expression PD-L1≥ 50% without mutations in …